We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

2nd SCI/RSC Fibrosis Medicinal Chemistry Symposium - Event Preview

2nd SCI/RSC Fibrosis Medicinal Chemistry Symposium Friday 10 November 2017

10 August 2017

Venue: SCI, London, UK
Date: Friday 10 November 2017

Fibrosis disease can manifest in many areas of the body, the result of a disregulated wound healing process after injury, which can lead to high mortality. With two drugs recently reaching marketed status for IPF (Idiopathic Pulmonary Fibrosis), there is continued growth and investment to identify new treatments, including for other conditions such as liver fibrosis and diabetic nephropathy. Fibrosis has complex disease pathology and greater knowledge of mechanisms is sought.

This autumn, SCI's Fine Chemicals Group and the RSC’s Biological and Medicinal Chemistry Sector are pleased to present the 2nd Fibrosis Medicinal Chemistry Symposium. The event will cover drug discovery and medicinal chemistry aspects of fibrotic conditions from leading experts in the field.

The programme and speakers will include:

  • An overview of liver and kidney fibrosis
    Dr Fiona Oakley, University of Newcastle, UK
  • Idiopathic pulmonary fibrosis: Impact of current treatments, limitations and opportunities
    Dr Hannah Woodcock, University College London, UK
  • αv integrin modulators for fibrosis and the profile of an αvβ6 clinical candidate
    Dr Simon Macdonald, GlaxoSmithKline, UK
  • Discovery and development of galectin-3 ligand mimetics as anti-fibrosis compounds
    Prof Ulf Nilsson, Lund University, Sweden
  • Discovery of GLPG1690: a first-in-class autotoxin inhibitor in clinical development for the treatment of idiopathic pulmonary fibrosis
    Dr Nicolas Desroy, Galapagos, France
  • Porcupine inhibitors as anti-fibrotic therapies
    Dr Cliff Jones, Redx Pharma Plc, UK
  • Cannabinoid Receptor (CB1R) based dual-target approaches for the treatment of fibrotic conditions
    Dr Malliga Iyer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA

The symposium will be of interest to researchers, academics, students and industrialists with an interest in fibrosis disease, medicinal chemistry and drug discovery.

Early bird fees apply before Friday 29 September and SCI members attending this meeting can claim CPD points.

CPD Accreditation

Related Links


Share this article